Skip to main content
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. — Investor Relations & Filings

Ticker · INKT ISIN · US6036931029 LEI · 529900Z7778N8ZY89B90 US Manufacturing
Filings indexed 226 across all filing types
Latest filing 2021-01-22 Capital/Financing Update
Country US United States of America
Listing US INKT

About MiNK Therapeutics, Inc.

https://www.minktherapeutics.com

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. The company's platform harnesses the dual properties of iNKT cells, which combine the potent cytotoxicity of natural killer (NK) cells with the lasting memory response of T cells to enhance both innate and adaptive immunity. Its lead product candidate, AGENT-797, is an off-the-shelf therapy administered without requiring lymphodepletion or HLA matching. It is currently in clinical trials for solid tumors, severe acute respiratory distress syndrome (ARDS), and Graft versus Host Disease (GvHD). MiNK is also developing a next-generation technology platform for engineered iNKT cells and bispecific iNKT cell engagers for precision targeting.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission under the Securities Act of 1933. It is a preliminary prospectus for an initial public offering (IPO) of common stock by AgenTus Therapeutics, Inc. The text includes detailed information typical of an IPO registration statement, such as risk factors, use of proceeds, capitalization, dilution, selected financial data, management discussion and analysis, business description, management and executive compensation, principal stockholders, and underwriting details. This type of filing is a capital markets document related to fundraising and securities issuance, not a financial report, earnings release, or management report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report. Hence, the classification is CAP with high confidence.
2021-01-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.